$GH · Guardant Health, Inc.
Guardant Health filed its Q3 2026 10-Q. Total revenue grew 36% YoY to $361.0M, driven by screening revenue up 180% to $67.6M and oncology up 25% to $231.3M. Net loss widened to $124.4M ($0.93/share) from $92.7M ($0.74/share), with operating loss of $132.8M. Nine-month revenue reached $997.6M versus $700.8M, with a nine-month net loss of $356.6M.
- Q3 revenue $361.0M, up 36% YoY from $265.2M.
- Screening revenue $67.6M, up 180% YoY from $24.1M.
- Net loss $124.4M ($0.93/share) vs $92.7M ($0.74/share) a year ago.
- Operating loss $132.8M vs $99.0M; operating margin -36.8%.
- Cash and equivalents $1.03B, up from $378.2M at year-end 2025.
Extended-hours last trade $137.44, down 10.42% vs the $153.43 regular close, signaling a negative after-hours reaction to the widening loss despite strong revenue growth.
Strong 36% revenue growth and 180% screening surge are offset by a widening loss, testing whether growth can translate to profitability.
Precision oncology peers are being rewarded for top-line growth, but Guardant's expanding operating loss and heavy stock-based compensation ($62.4M in Q3) weigh on profitability optics.
Widening net loss and negative stockholders' deficit of $275.9M; $1.50B convertible senior notes outstanding. Heavy stock-based compensation ($167.8M nine months) dilutes shareholders.